CureGRIN Foundation

CureGRIN Foundation is dedicated to improving the lives of people around the world with GRI Disorders, and their families, through research, education and connectivity. We work closely with scientists and the medical community to drive patient-centered research that will lead to treatments and cures.

CureGRIN drives treatments and cures for GRIN, GRIA, GRIK and GRID Disorders by 1) Helping scientists to prioritize and fund patient-centered research, 2) Partnering with pharmaceuticals to develop treatments and cures for GRI Disorders 3) Advancing clinical-trial readiness across the global GRI community.4) Championing advocacy for people with GRI and their families to governments, regulators and funding agencies, and 5) Educating and connecting the global GRI community of patient families, researchers, clinicians and industry.

CureGRIN was founded in 2019 by a group of GRIN1 parents determined on finding treatments and cures for all GRI Disorders. In 2020, CureGRIN was selected by Chan Zuckerberg Initiative to receive a $600,000 grant and be part of its Rare as One Initiative. This accelerated the organization's growth and allowed it to begin hiring paid employees. In 2022, CureGRIN expanded its focus to include all GRI genes.

GRI Disorders are a set of rare, genetic, neurodevelopmental disorders involving pathogenic variants in one of the genes that encode ion glutamate receptors (NMDA, AMPA, Kainate or Delta receptors. These disorders include GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIA2, GRIA3 and GRIK2-related neurodevelopmental disorders. GRI disorders present with a spectrum of symptoms including intellectual and physical disabilities, epilepsy, movement disorders, dysautonomia, and complications related to vision, sleep and gastrointestinal health